DelveInsight’s ‘Cystic Fibrosis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Cystic Fibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystic Fibrosis pipeline domain.
Key Takeaways from the Cystic Fibrosis Pipeline Report
- Over 80+ Cystic Fibrosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Cystic Fibrosis market would significantly increase market revenue.
- Leading Cystic Fibrosis companies developing novel drug candidates to improve the Cystic Fibrosis treatment landscape include Algi Pharma, Verona Pharma, Translate Bio, Calithera Biosciences, Krystal Biotech, SpliSense, and others.
- Promising Cystic Fibrosis pipeline therapies in various stages of development include OligoG, Ensifentrine, MRT5005, CB280, KB407, SPL84231, and others.
Cystic Fibrosis Overview
Cystic fibrosis is a disorder that damages your lungs, digestive tract and other organs. It’s an inherited disease caused by a defective gene that can be passed from generation to generation. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices.
Cystic Fibrosis Pipeline Analysis: Drug Profile
OligoG: Algi Pharma
OligoG is formulated as a dry powder for inhalation and is AlgiPharma’s lead drug candidate. It is an alginate oligosaccharide derived from seaweed, and is a new class of drug which is modulating mucus and normalizing mucus rheology. It is being developed to help people with cystic fibrosis clear mucus from their lungs. It is anticipated that OligoG may help to slow the progression of the disease. OligoG has been shown to disrupt the infectious biofilm often present in the lungs of individuals with CF. This biofilm disruption is believed to improve antibiotic effectiveness by increasing exposure of bacteria to antibiotics. It is in Phase 2 stage of development for the treatment of Cystic Fibrosis.
Discover more about the emerging Cystic Fibrosis drugs @ Cystic Fibrosis Treatment Drugs
Cystic Fibrosis Key Companies
- Algi Pharma
- Verona Pharma
- Translate Bio
- Calithera Biosciences
- Krystal Biotech
Cystic Fibrosis Pipeline Therapies
Cystic Fibrosis Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Cystic Fibrosis Pipeline Report
- Coverage: Global
- Key Cystic Fibrosis Companies: Algi Pharma, Verona Pharma, Translate Bio, Calithera Biosciences, Krystal Biotech, SpliSense, and others
- Key Cystic Fibrosis Pipeline Therapies: OligoG, Ensifentrine, MRT5005, CB280, KB407, SPL84231, and others
Find out more about the Cystic Fibrosis treatment options in development @ Cystic Fibrosis Clinical Trials
Table of Contents
2. Executive Summary
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
16. About DelveInsight
Request for a sample report @ Cystic Fibrosis Clinical Trials
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States